HIGHLIGHTS
- who: Mahdi Barzegar and collaborators from the Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran have published the research: Association of Disease-Modifying Therapies with COVID-19 Susceptibility and Severity in Patients with Multiple Sclerosis: A Systematic Review and Network Meta-Analysis, in the Journal: Multiple Sclerosis International of 21/09/2022
- what: The study showed an increased risk of severe COVID-19 in patients on rituximab and ocrelizumab. This study showed that patients on anti-CD20 agents had highest rates of hospitalization and mortality than those on other DMTs. Four studies . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.